Pyrrolotriazinone As an Underexplored Scaffold in Drug Discovery

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2021 Dec 28

PMID 34959675

Authors

Tony Ge

Jean-Christophe Cintrat

Affiliations

Soon will be listed here.

Abstract

Heterocyclic amino derivatives have been extensively synthesized and validated as potent bioactive compounds, and nowadays, numerous marketed drugs share these scaffolds, from very simple structures (monoamino, monocyclic compounds) to much more complex molecules (polycyclic derivatives with two or more nitrogen atoms within the (fused) rings). In a constant quest for new chemical entities in drug discovery, a few novel heterocycles have emerged in recent years as promising building blocks for the obtainment of bioactive modulators. In this context, pyrrolotriazinones have attracted attention, and some show promising biological activities. Here, we offer an extensive review of pyrrolo[2,1-f][1,2,4]triazin-4(1H)-one and pyrrolo[1,2-d][1,2,4]triazin-4(3H)-one, describing their biological properties en route to drug discovery.

References

Zhang M, Jang H, Nussinov R . PI3K inhibitors: review and new strategies. Chem Sci. 2020; 11(23):5855-5865. PMC: 7472334. DOI: 10.1039/d0sc01676d. View

Pissios P, Trombly D, Tzameli I, Maratos-Flier E . Melanin-concentrating hormone receptor 1 activates extracellular signal-regulated kinase and synergizes with G(s)-coupled pathways. Endocrinology. 2003; 144(8):3514-23. DOI: 10.1210/en.2002-0004. View

Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D . Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation. 2001; 104(8):921-7. DOI: 10.1161/hc3401.093152. View

Fujita M, da Luz Scheffer D, Lenfers Turnes B, Cronin S, Latremoliere A, Costigan M . Sepiapterin Reductase Inhibition Leading to Selective Reduction of Inflammatory Joint Pain in Mice and Increased Urinary Sepiapterin Levels in Humans and Mice. Arthritis Rheumatol. 2019; 72(1):57-66. PMC: 6935418. DOI: 10.1002/art.41060. View

Fox S, May J, Johnson A, Hermann D, Strieter D, Hartman D . Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers. Platelets. 2012; 24(5):392-400. DOI: 10.3109/09537104.2012.704648. View

Wang Y, Wu X, Du M, Chen X, Ning X, Chen H . Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation. Oncotarget. 2017; 8(26):42510-42524. PMC: 5522084. DOI: 10.18632/oncotarget.17207. View

Weber A . Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem. 2004; 47(17):4135-41. DOI: 10.1021/jm030628v. View

Tache Y . Corticotropin releasing factor receptor antagonists: potential future therapy in gastroenterology?. Gut. 2004; 53(7):919-21. PMC: 1774121. DOI: 10.1136/gut.2003.036400. View

Singh N, Patra S . Phosphodiesterase 9: insights from protein structure and role in therapeutics. Life Sci. 2014; 106(1-2):1-11. DOI: 10.1016/j.lfs.2014.04.007. View

10.

Gross S, Tilly P, Hentsch D, Vonesch J, Fabre J . Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J Exp Med. 2007; 204(2):311-20. PMC: 2118736. DOI: 10.1084/jem.20061617. View

11.

Shao Y, Huang M, Cui W, Feng L, Wu Y, Cai Y . Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent. J Med Chem. 2014; 57(24):10304-13. PMC: 4281101. DOI: 10.1021/jm500836h. View

12.

Jia H, Dai G, Su W, Xiao K, Weng J, Zhang Z . Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors. J Med Chem. 2019; 62(10):4936-4948. DOI: 10.1021/acs.jmedchem.8b02014. View

13.

Erra M, Taltavull J, Bernal F, Caturla J, Carrascal M, Pages L . Discovery of a Novel Inhaled PI3Kδ Inhibitor for the Treatment of Respiratory Diseases. J Med Chem. 2018; 61(21):9551-9567. DOI: 10.1021/acs.jmedchem.8b00873. View

14.

Tracz-Gaszewska Z, Dobrzyn P . Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer. Cancers (Basel). 2019; 11(7). PMC: 6678606. DOI: 10.3390/cancers11070948. View

15.

Vitaku E, Smith D, Njardarson J . Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. J Med Chem. 2014; 57(24):10257-74. DOI: 10.1021/jm501100b. View

16.

Saito T, Obitsu T, Kohno H, Sugimoto I, Matsushita T, Nishiyama T . Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF₁) receptor antagonists. Bioorg Med Chem. 2011; 20(2):1122-38. DOI: 10.1016/j.bmc.2011.11.015. View

17.

Montoir D, Guillon R, Gazzola S, Ourliac-Garnier I, Soklou K, Tonnerre A . New azole antifungals with a fused triazinone scaffold. Eur J Med Chem. 2020; 189:112082. DOI: 10.1016/j.ejmech.2020.112082. View

18.

Corbin J . Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res. 2004; 16 Suppl 1:S4-7. DOI: 10.1038/sj.ijir.3901205. View

19.

Erra M, Taltavull J, Greco A, Bernal F, Caturla J, Gracia J . Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases. ACS Med Chem Lett. 2017; 8(1):118-123. PMC: 5238472. DOI: 10.1021/acsmedchemlett.6b00438. View

20.

Oatman N, Dasgupta N, Arora P, Choi K, Gawali M, Gupta N . Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. Sci Adv. 2021; 7(7. PMC: 7875532. DOI: 10.1126/sciadv.abd7459. View